ClinicalTrials.gg
RecruitingNCT07202559Updated Apr 13, 2026

Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy

An interventional study of Indometacin suppository and Lactated ringers solution in Pancreatitis, Chronic, Pancreatitis, Acute and Pancreatic Duct Stones, sponsored by Changhai Hospital. Recruiting at 10 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Pancreatitis, Chronic by Changhai Hospital — 13 open to participants now, 18 under way, none of them phase 3. Pancreatitis, Chronic · Changhai Hospital.

Planned enrollment
2nd of 13
1,250 · median 134
Started
2025
with 8 others
No phase
11 of 41
3 open now
Primary completion
2027-12
later than 11 of 17 live
Registered
38th of 41
by date

Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 9 that started in 2025, is one of 11 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 38th registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

13 of the 41 studies in Pancreatitis, Chronic by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pancreatitis, Chronic by Changhai Hospital, or all of them as a file.
02

Study summary

This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.

The study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.

The trial will be conducted at multiple centers, ensuring a broad and diverse patient population.

The primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.

This study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.

03

Conditions studied

  • Pancreatitis, Chronic
  • Pancreatitis, Acute
  • Pancreatic Duct Stones
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with painful chronic pancreatitis eligible for P-ESWL treatment
  • Ages between 18-85 years
  • Providing

Exclusion criteria

Exclusion Criteria:

  • Patients readmitted to the hospital for ESWL during the study period
  • to ESWL
  • Signs of congestive heart failure, such as pitting edema or a classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP>100pg/ml or value\<50% should be excluded
  • Respiratory insufficiency (pO2 \< 60 mmHg or saturation \< 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with (FEV1) \<70% are excluded
  • Patients receiving more than 1.5 mL/kg/h or 3 L/24 h of intravenous fluids in the 24 h before ESWL
  • Hypotension (systolic blood pressure \<90 mmHg or mean arterial pressure \<70 mmHg)
  • Hypo- or hypernatremia (serum Na+ levels \< 130 or > 150 mmol/L)
  • Severe liver disease (cirrhosis with ascites, liver abscess)
  • receiving NSAIDs within 7 days
  • Contraindications for rectal use of NSAIDs (renal dysfunction with serum creatinine >120 μmol/L, allergy, active gastrointestinal bleeding, ulcer disease, and NSAID use for other indications [other than cardioprotective aspirin])
  • presence of coagulopathy or received anticoagulation therapy within 3 days
  • acute pancreatitis within 3 days
  • known active cardiovascular or cerebrovascular disease
  • pregnant or breastfeeding women
  • without a rectum (ie, status post-total proctocolectomy)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,250 participants (estimated)

Study arms

  • Active comparator
    Rectal indometacin alone

    Participants in this arm will receive a rectal administration of 100mg indometacin 30 minutes prior to ESWL. This group will not undergo aggressive hydration and will instead receive restricted hydration measures.

    Drug: Indometacin suppository · Drug: Normal Saline

  • Experimental
    Aggressive hydration with rectal Indometacin

    Participants in this arm will also receive a rectal administration of 100mg indometacin 30 minutes before ESWL. In addition, they will undergo aggressive intravenous hydration using lactated Ringer's solution.

    Drug: Indometacin suppository · Drug: Lactated ringers solution

Interventions

  • DrugIndomethacinStudies of IndomethacinIndomethacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of a 100mg indometacin suppository rectally 30 minutes prior to ESWL

  • DrugRinger's LactateStudies of Ringer's LactateRinger's Lactate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.

  • DrugNormal Saline

    Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h)

06

What researchers measure

Primary outcomes

  1. Incidence of post-ESWL pancreatitis

    Post-ESWL pancreatitis is defined according to the 2012 Atlanta criteria. A diagnosis of post-ESWL pancreatitis is made if two of three of the following criteria are met: pain consistent with pancreatitis; amylase or lipase of at least three times the upper normal limit within 24 h of the procedure; or characteristic findings on imaging.

    Time frame: 24 hours

Secondary outcomes

  1. Severity of pancreatitis

    Stratified as mild, moderate, or severe, mainly on the basis of length of hospitalization and need for invasive treatment.

    Time frame: 1 month

  2. Incidence of other post-ESWL complications

    Including bleeding, infection, steinstrasse, and perforation.

    Time frame: 24 hours

  3. Incidence of fluid overload

    Including pulmonary or peripheral edema and congestive heart failure.

    Time frame: 24 hours

  4. Transient adverse events related to ESWL

    Transient adverse events were defined as transient injuries caused by shock waves that required no medical intervention and did not prolong hospitalisation, including asymptomatic hyperamylasaemia, haematuria, and acute gastrointestinal mucosal injury (eg, haematemesis, melena, or haem atochezia) caused by ESWL. Asymptomatic hyper amylasaemia was defined as an increase in serum amylase compared with pre ESWL levels and beyond the upper limit of the normal range but showing no related symptoms.

    Time frame: 24 hours

  5. Length of hospitalisation

    Time frame: 1 month

07

Study locations

8 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 46 non-industry interventional studies with no phase under Pancreatitis, Chronic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 25 months is below that.

Counting every sponsor, half of 49 studies reached it within 32 months; a quarter within 18 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 2, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07202559
Lead sponsor
Changhai Hospital
Collaborators
Ruijin Hospital, LanZhou University, First People's Hospital of Hangzhou, The Second Affiliated Hospital of Baotou Medical College, Shanghai Pudong New Area Gongli Hospital, Peking Union Medical College Hospital, Qilu Hospital of Shandong University, The Third Xiangya Hospital of Central South University, Affiliated Hospital of Yunnan University
Responsible party
Zhaoshen Li (Professor, Changhai Hospital) — Principal investigator
First posted
Oct 2, 2025
Start date
Oct 13, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Liang-Hao Hu
Contact
lianghao-hu@hotmail.com
+8613817593520

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ringer's Lactate

Start the discussion